An AI-enabled diagnostics firm has begun a new multi-center trial with Mount Sinai, and medical schools at Yale, the University of Michigan Medical School, Johns Hopkins, and Rutgers to predict long-term kidney disease risk in recovering COVID-19 patients.
from Mount Sinai, Yale, Johns Hopkins to track chronic kidney disease in COVID survivors
https://ift.tt/3kD5WgP
https://ift.tt/eA8V8J
No comments:
Post a Comment